Regulatory Focus™ > News Articles > 5 > Recon: Novartis Lawyer Exits Over Cohen Payments

Recon: Novartis Lawyer Exits Over Cohen Payments

Posted 16 May 2018 | By Ana Mulero 

Recon: Novartis Lawyer Exits Over Cohen Payments

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US [Paid Advertisement]
Currently, approximately 70% of IVDs on the market are sold without the involvement of a Notified Body. The IVDR will change that while also making sweeping changes to medical device regulations, all aimed at protecting end users.

Join us on May 16th at 11:00am EDT for our complimentary webinar Overview of the New European IVDR and find out how you can prepare your business for the transition.
Register now

In Focus: International
  • Credit Suisse to pump $250 million into Israeli health tech venture fund aMoon (Times of Israel) (The Financial) (Endpoints)
  • Vermont becomes first state to permit drug imports from Canada (Politico) (The Hill)
  • SA Health blood test delays and lost results blamed on new computer system (ABC) (Healthcare IT News) (SBS News)
  • Picking your pharma right: Why alienate US with stent regulations or compulsory licensing? (Financial Express)
  • BC Platforms, Google Cloud partner to offer transformational and scalable genomic solutions worldwide (Pharmabiz)
  • Congo receives first doses of Ebola vaccine amid outbreak (Reuters)
  • Novartis' Sandoz business is broken, CEO says, but he's focused on fixing it (Fierce)
  • Tariffs on Chinese Goods May Trigger Drug, Device Shortages (Bloomberg-$)
Pharmaceuticals & Biotechnology
  • What New Jersey's drug plan do-over says about the industry (Axios)
  • Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million (Forbes)
  • FDA reverses course on Duke’s research grant after favoritism concerns (Politico)
  • Valeant Ex-CEO Wasn't Swayed by Philidor Warning, Witness Says (Bloomberg)
  • Peer review could have helped short-circuit the Theranos fake news scandal (STAT)
  • It’s a long-shot idea for a major Medicare change. But drug makers are already scared (STAT-$)
  • AbbVie bows to pressure to keep cheaper Imbruvica formula on the market (Fierce)
  • Eleven rebrands as Sesen as data readout nears (Fierce) (Press)
  • Ex-Pfizer executives join Roivant's C-suite (Fierce) (Press)
  • J&J CEO warns of 'unintended consequences' of Trump's drug-price reduction plan (CNBC)
  • No Jurisdiction Over NDA Holder Who Did Not Make The Drug (Lexology-$)
  • Insys Bribed Docs To Write Opioid Scripts, DOJ, 6 States Say (Law360-$)
  • 3rd Circ. Already OK'd Lipitor State Claims, Health Plans Say (Law360-$)
  • FDA reports quality problems for data provided by the firm IQVIA that were used to inform estimates for some controlled substances (FDA)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Seattle’s Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials (Endpoints) (Press)
  • His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor (Endpoints)
  • Lilly's cluster buster puts Amgen in a fluster (EP Vantage)
  • Asco preview – lung cancer battle takes centre stage (EP Vantage)
  • Merck, Eiger expand drug licensing deal to include rare disease indication (BioPharma Dive)
  • Researchers Uncover Gut Bacteria's Potential Role In Multiple Sclerosis (Forbes)
  • FDA expands Truvada indication (The Pharma Letter)
  • Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine (JAMA)
  • Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease (Press)
  • Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies (Press)
  • Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC (Press)
  • Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250 (Press)
  • Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy (Press)
Medical Devices
  • Auris Health, Ethicon’s NeuWave ink robot-assisted bronchoscope ablation dev deal (MassDevice)
  • Stryker’s Howmedica owes $13m in fees in Zimmer Biomet patent spat (MassDevice)
  • 'Program Alignment' Turns 1: FDA Wants To Train Investigators On Innovative Tech As Part Of Its Inspection Scheme – But Will It Be A Cakewalk? (Medtech Insight-$)
  • iSTAR's Glaucoma Micro Device Shines In Early Follow-Up (Medtech Insight-$)
  • Sivantos and Widex in $8 billion merger to create No.3 in hearing aids (Reuters)
  • Sivantos-Widex allows EQT to reset the clock (EP Vantage)
  • Keys To FDA Advisory Panel Prep For Device Makers (Law360-$)
  • MC10 Receives FDA 510(k) Clearance for the BioStamp nPoint System (Press)
  • FDA Clears CASMED’s FORE-SIGHT Tissue Oximetry OEM Module (Press)
  • Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease (Press)
  • DePuy Synthes Signs Definitive Agreement to Acquire Assets of Medical Enterprises Distribution, LLC to Strengthen its Portfolio and Amplify the Surgeon's Capabilities Via Automation (Press)
US: Assorted & Government
  • Verily submitted patent application for smart diaper able to detect, differentiate between waste (MobiHealthNews)
  • Pennsylvania Appeals Court Affirms Preemption of State Law Claims Based on Off-Label Marketing (FDA Law Blog)
  • Blue states can defend ACA in latest lawsuit, judge says (Axios)
  • Which drug makers’ medicines are racking up bigger and bigger bills for Medicare and Medicaid? (STAT-$)
  • Johnson & Johnson to relaunch baby-care line after its 20% sales decline (CNBC)
  • A bid to save $300 million at HCR ManorCare, and disrupt U.S. healthcare (Reuters)
  • Pennsylvania To Lead Nation In Medical Marijuana Research (Forbes)
  • Elliott Says Athenahealth Isn't Engaging in Takeover Talks (Bloomberg)
  • International Mail Facilities: ORA Letter to the USPS (FDA)
  • Fixing Healthcare: Driving Value Through Smart Purchasing and Policy (HHS Secretary Alex Azar)
Upcoming Meetings & Events Europe
  • CGT Catapult unveils major UK investment in skills and capabilities (PharmaTimes)
  • Interoperability also posing big challenges in the UK (HealthcareITNews)
  • GDPR: The Multiple Ways In Which Medtech Is Impacted, And Needs To Comply (Medtech Insight-$)
  • Reva touts first implant of bioresorbable scaffold in Turkey (Drug Delivery Business News)
  • Amgen Receives European Commission Approval For Repatha (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease (Press)
  • GE increases cell culture media production capacity by tenfold (Press)
  • Philips and Dutch Rijnstate hospital sign 10-year agreement to build a virtual hospital for large-scale connected care (Press)
Asia India
  • MedGenome, Kailash Cancer Hospital discover genetic mutation of rare colorectal disorder in Gujarati family (Pharmabiz)
  • Local medical devices industry wants Modi to encourage indigenous manufacturing (Business Today)
Australia Canada
  • Medical students, health groups call on province to cover abortion pill (CBC News)
  • Half of Canadians have experienced a mental health issue (Sun Life Financial Canada)
General Health & Other Interesting Articles
  • Suicide Became the Second Leading Cause of Death for Young People in 2016. We Don't Know Why (Fortune)
  • Survey: Nine out of ten doctors worry about negative online reviews (MobiHealthNews)
  • Why EHR data interoperability is such a mess in 3 charts (HealthcareITNews)
  • Trump’s Plan for Cheaper Health Insurance Could Have Hidden Costs (NYT)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.
Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.